LoginSignup
immagine del profilo
Mona.Ohls ex Boersen.Bulle
@Boersen_Bulle
3Anno·
Opinione per $MOR

Founded in 1992 in Martinsried near Munich, Germany, MorphoSys AG is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies in the areas of cancer and autoimmune diseases.


MorphoSys is advancing its proprietary pipeline of new drugs based on its leading expertise in antibody and protein technology.


The focus is on therapies in the field of oncology (benign and malignant tumor types as well as cancer). Based on its expertise in antibody, protein and peptide technologies.


Morphosys partner companies include the following international pharmaceutical companies: Bayer Pharma AG, Boehringer Ingelheim, Novartis AG, Johnson & Johnson, Merck & Co., Pfizer, Roche


Latest news: Morphosys announced in mid-October that its licensing partner Roche has received "breakthrough therapy" status for its Alzheimer's drug gantenerumab.


Current share price: € 39.15

Performance 3 years: -49.66

Performance 5 years: -5.33


Do you already know the German company?


---------------


Not an investment recommendation - Source: Wikipedia, deraktionaer

attachment
5
18 Commenti
immagine del profilo
Max@Max21
3Anno
How do you see the company and the share price in the medium to long term?
•
1
•
Visualizza tutti 7 ulteriori risposte
immagine del profilo
Stefan@InvestmentPapa
3Anno
Interesting to read, yes. But as a company, I didn't read it on the screen. I tend to be with the big global players when it comes to biotech and health. For me, the risk with the small companies is just too big. Morphosys has also made some strange decisions on the part of management in the past, after all. I don't need any turmoil in that respect, but thank you for the introduction.
•
1
•
Mostra la risposta
immagine del profilo
Alfred Wilhelm@GymTonic
3Anno
Oh dear , the days of "Mr. Dausend" are long gone and quite definitely passé.
I had my first great profit-taking with this company...
Repeat attempts failed miserably ...
A prime example of a share that always goes one better when you think it can't go any lower ...
I'll take a look at it again at around 27 euros, it will still make it ...
•
1
•
Visualizza tutti 2 ulteriori risposte
immagine del profilo
Markus@RealPortfolio
3Anno
Biotech is a difficult bet. MorphoSys is a good company, but as is usual in the industry, it is all very, very protracted and the prospects of success are unclear for a long time and success is rare.
My opinion is that it is best to diversify in a sector ETF if you want to be involved.

If you're very lucky, you might catch a new Biontech or Moderna. But this is very unlikely. In the case of news such as Roche and Gantenerumab mentioned above, always check who gets how much of the cake in the event of success.
•
1
•
Utente eliminato
3Anno
Il commento è stato cancellato
Visualizza tutti 2 ulteriori risposte
Utente eliminato
3Anno
Il commento è stato cancellato
Mostra la risposta
Partecipa alla conversazione
IscrivitiAccesso